Showing 3421-3430 of 5661 results for "".
- FDA Takes First Step Toward Expanding Sunscreen Optionshttps://practicaldermatology.com/news/fda-takes-first-step-toward-expanding-sunscreen-options/2484881/The American Academy of Dermatology Association (AADA) released a statement from organization president Susan C. Taylor, MD, FAAD commending the Food and Drug Administration (FDA) for taking its first significant step in more than 20 years toward expanding safe and
- Moisturizer Effective in Acne Patients Using Topical Therapies: Analysishttps://practicaldermatology.com/news/moisturizer-boosts-skin-barrier-in-acne-patients-using-topical-therapies/2484743/New research showed a novel gel-matrix moisturizer improving skin barrier function and overall skin quality in adults with acne undergoing topical treatment. Researchers from Kenvue and Dermatology Consulting Services evaluated
- Lupus-like Skin Disease in MDS/CMML Linked to Clonal Inflammation: Studyhttps://practicaldermatology.com/news/lupuslike-skin-disease-in-mdscmml-linked-to-clonal-inflammation/2484592/Lupus-like manifestations in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) appear to represent a distinct clinical entity driven by clonal hematopoiesis rather than classic autoimmunity, according to a new case-control study
- Seborrheic Dermatitis Linked to Systemic Epithelial Barrier Diseases: Analysishttps://practicaldermatology.com/news/seborrheic-dermatitis-linked-to-systemic-epithelial-barrier-diseases-analysis/2484390/Findings from a new retrospective cohort suggest individuals living with seborrheic dermatitis are more likely to have other epithelial barrier diseases such as rosacea, alopecia areata, and celiac disease. Investigators publish
- FDA Warns Websites Selling Unapproved Botulinum Toxin Productshttps://practicaldermatology.com/news/fda-warns-websites-selling-unapproved-botulinum-toxin-products/2484341/The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including sym
- Lebrikizumab Maintains Efficacy With Reduced Dosing Intervalhttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-with-reduced-dosing-interval/2484255/Long-term data from a 32-week extension of the ADjoin trial suggest that lebrikizumab, an IL-13 inhibitor approved for once-monthly dosing, may maintain clinical efficacy in patients with moderate-to-severe atopic dermatitis (AD) even when administered once every 8
- Topical Caffeine May Provide Hair Growth Benefit for Alopecia: Studyhttps://practicaldermatology.com/news/topical-caffeine-may-provide-hair-growth-benefit-for-alopecia-study/2484243/Topical caffeine may be a promising adjunct treatment for hair loss, according to a systematic review published in the Journal of Drugs in Dermatology. The analysis assessed original studies investigating caffeine’s effects on hair growth across multiple fo
- Dr. Peter Lio Named Fall Clinical Educator of the Yearhttps://practicaldermatology.com/news/dr-peter-lio-named-fall-clinical-educator-of-the-year/2484092/Peter Lio, MD, was presented with the Educator of the Year Award at the 2025 Fall Clinical Dermatology Conference. Dr. Lio is founding director of the Chicago Integrative Eczema Center and a member of Practical Dermatology’s Editorial Board. Dr. Lio spoke at the Fall Clinical Meetin
- Study Links Structural and Immune Risk Factors to Skin Conditions in PWHhttps://practicaldermatology.com/news/study-links-structural-and-immune-risk-factors-to-skin-conditions-in-pwh/2483949/Nearly half of people living with HIV (PWH) are diagnosed with at least one dermatologic condition despite advances in antiretroviral therapy (ART), according to a longitudinal cohort study published through the DC Cohort. Accor
- FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCChttps://practicaldermatology.com/news/fda-approves-libtayo-for-adjuvant-treatment-of-high-risk-cscc/2483899/The FDA has approved cemiplimab-rwlc (Libtayo, Regeneron) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence following surgery and radiation, according to a statement from the agency.